» Articles » PMID: 9741497

The Influence of Diabetes Mellitus on Acute and Late Clinical Outcomes Following Coronary Stent Implantation

Overview
Date 1998 Sep 19
PMID 9741497
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We compared the clinical outcomes following coronary stent implantation in insulin-treated diabetes mellitus (IDDM), non-IDDM patients, and nondiabetic patients.

Background: Diabetic patients have increased restenosis and late morbidity following balloon angioplasty. The impact of diabetes mellitus (DM), especially IDDM, on in-stent restenosis is not known.

Methods: We studied 954 consecutive patients with native coronary artery lesions treated with elective Palmaz-Schatz stents implantation using conventional coronary angiographic and intravascular ultrasound methodology. Procedural success, major in-hospital complications, and 1-year clinical outcome were compared according to the diabetic status. RESULTS. In-hospital mortality was 2% in IDDM, significantly higher (p <0.02) compared with non-IDDM (0%) and nondiabetics (0.3%). Stent thrombosis did not differ among groups (0.9% in IDDM vs. 0% in non-IDDM and 0% in nondiabetics, p >0.1). During follow-up, target lesion revascularization (TLR) was 28% in IDDM, significantly higher (p <0.05) compared with non-IDDM (17.6%) and nondiabetics (16.3%). Late cardiac event-free survival (including death, myocardial infarction [MI], and any coronary revascularization procedure) was significantly lower (p=0.0004) in IDDM (60%) compared with non-IDDM (70%) and nondiabetic patients (76%). By multivariate analysis, IDDM was an independent predictor for any late cardiac event (OR=2.05, p=0.0002) in general and TLR (odds ratio=2.51, p=0.0001) in particular. CONCLUSIONS. In a large consecutive series of patients treated by elective stent implantation, IDDM patients were at higher risk for in-hospital mortality and subsequent TLR and, as a result, had a significantly lower cardiac event-free survival rate. On the other hand, acute and long-term procedural outcome was found to be similar for non-IDDM compared with nondiabetic patients.

Citing Articles

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials.

Sun X, Zhang C, Ma Y, He Y, Zhang X, Wu J Cardiovasc Diabetol. 2024; 23(1):132.

PMID: 38650038 PMC: 11036687. DOI: 10.1186/s12933-024-02201-6.


Prediabetes and major adverse cardiac events after acute coronary syndrome: An overestimated concept.

Behnoush A, Maleki S, Arzhangzadeh A, Khalaji A, Pezeshki P, Vaziri Z Clin Cardiol. 2024; 47(4):e24262.

PMID: 38558072 PMC: 10983809. DOI: 10.1002/clc.24262.


SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis.

Zhang Q, Deng Z, Li T, Chen K, Zeng Z Front Cardiovasc Med. 2024; 10:1280547.

PMID: 38274313 PMC: 10808651. DOI: 10.3389/fcvm.2023.1280547.


Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial.

Seeger J, Wohrle J, Scheller B, Farah A, Ohlow M, Mangner N J Cardiovasc Dev Dis. 2023; 10(3).

PMID: 36975883 PMC: 10057565. DOI: 10.3390/jcdd10030119.


Which Stent for Diabetic Patient With Coronary Artery Disease?.

Hong M, Hong S JACC Asia. 2022; 1(2):185-186.

PMID: 36338171 PMC: 9627909. DOI: 10.1016/j.jacasi.2021.07.010.